NCT05445323View on ClinicalTrials.gov

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Friedreich AtaxiaCardiomyopathy, Secondary
Interventions
GENETIC

Low dose LX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

GENETIC

Mid Dose LX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

GENETIC

High Dose LX2006

Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

Trial Locations (3)

33612

University of South Florida, Tampa

55905

Mayo Clinic, Rochester

90095

Ataxia Center and HD Center of Excellence, University of California, Los Angeles

Sponsors

Lead Sponsor

Lexeo Therapeutics
All Listed Sponsors
lead

Lexeo Therapeutics

INDUSTRY